Resources
Functional network integrity presages cognitive decline in preclinical Alzheimer disease
Buckley RF, Schultz AP, Hedden T, Papp KV, Hanseeuw BJ, Marshall G, Sepulcre J, Smith EE, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP. Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology. 2017 Jul 4;89(1): 29-37. Doi: 10.1212/WNL.00000000004059. Epub 2017 Jun 7. PMID: 28592457.
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O’Bryant SE, Rabinovici GD, Rowe C, Slloway S, Scheider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”, July 23, 2015; diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. doi:10.1016/j.jal.2016.02002. Review. PMID:27012484
On the path to 2025: understanding the Alzheimer’s disease continuum
Aisen PS, Cummings, J, Jack CR Jr, Morris JC, Sperling R, Frolich L, Jones RW, Dowsett SA, Mathews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017 Aug 9;9(1): 60. Doi: 10.1186/s13195-017-0283-5. Review. PMID: 28793924
Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):280-92. doi:10.1016/j.jaz.2011.03.003.Epub 2011 Apr 21. PMID: 21514248
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
Clifford R. Jack, Jr., David A. Bennett, Kaj Blennow, Maria C. Carrillo, Billy Dunn, Samantha Budd Haeberlein, David M. Holtzman, William Jagust, Frank Jessen, Jason Karlawish, Enchi Liu, Jose Luis Molinuevo, Thomas Montine, Creighton Phelps, Katherine P. Rankin, Christopher C. Rowe, Philip Scheltens, Eric Siemers, Heather M. Snyder, Reisa Sperling; Contributors: Cerise Elliott, Eliezer Masliah, Laurie Ryan, and Nina Silverberg
“Alzheimer’s disease” is neither “Alzheimer’s clinical syndrome” nor “dementia”
Special Topic Section: Responses to the NIA-AA Research Framework. W. Jagust et al. / Alzheimer’s & Dementia 15 (2019) 153-157.
Commercial Alzheimer’s Disease biomarkers that have the potential to provide early detection are of paramount importance in determining disease progression.
About Us
Read more about Brainsymphonics & our company history & leadership.
Our Science
Our EBPS-AD software is based on a decade of AD research progress.
Alzheimer's Disease
Read about the effects of Alzheimer’s & AD development process.
BRAINSYMPHONICS
16600 W National Avenue
New Berlin, WI 53151